Hematopoietic Stem Cell Transplantation Market

Hematopoietic Stem Cell Transplantation Market Size, Market Forecast and Outlook By FMI

Summary of the Hematopoietic Stem Cell Transplantation Market

• Demand and Growth Drivers
  • Indication expansion is increasing the patient population eligible for HSCT.
  • Donor source diversification is improving transplant accessibility.
  • Post-transplant outcome improvement is supporting broader clinical adoption.
• Product and Segment View
  • Allogeneic transplants are expected to lead with 57.3% of transplant type demand in 2026.
  • Acute myeloid leukemia is expected to represent 38.5% of indication demand.
  • Peripheral blood stem cell transplants are expected to account for 47.6% of application demand.
• Geography and Competitive Outlook
  • South Korea (8.0%) and the EU (7.9%) are expected to lead growth.
  • The USA (7.7%) maintains growth through the highest global transplant volume.
  • Companies with cell therapy portfolios and transplant support products are expected to capture growth in the expanding transplant market.
• Analyst Opinion
  • The HSCT market is sustained by expanding clinical indications and improving transplant outcomes that support broader adoption.
  • Allogeneic transplantation growth is driven by donor source diversification and haploidentical transplant technique advancement.
  • The market is benefiting from improved GVHD management and supportive care that reduce transplant-related mortality.
  • Companies supporting the transplant pathway from cell processing through post-transplant complication management are expected to capture integrated value.

Key Takeaways, Market Size, and Forecast

• The hematopoietic stem cell transplantation market was valued at USD 8.15 billion in 2025.
• The market is projected to reach USD 8.8 billion in 2026 and USD 18.61 billion by 2036, growing at a CAGR of 7.8%.
• By 2036, the Hematopoietic Stem Cell Transplantation Market is expected to be worth USD 18.61 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 7.8%.
• The market is projected to create an incremental opportunity of USD 9.83 billion between 2026 and 2036.
• In 2026, allogeneic is expected to account for 57.3% of the transplant type segment, driven by strong clinical preference and expanding donor registries.
• Acute Myeloid Leukemia is expected to lead the application segment with a 38.5% share.
• South Korea (8.0%) and EU (7.9%) are two of the fastest growing markets in the world.

Hematopoietic Stem Cell Transplantation Market Definition

The hematopoietic stem cell transplantation market covers clinical services, pharmaceutical products, and supportive care associated with bone marrow and stem cell transplantation procedures for hematological malignancies, bone marrow failure syndromes, and immune deficiency conditions. Services include donor matching, conditioning regimens, transplantation procedures, and post-transplant management.

Hematopoietic Stem Cell Transplantation Market Inclusions

Market scope covers all commercially delivered HSCT services categorized by transplant type (allogeneic, autologous), indication (acute myeloid leukemia, lymphoma, multiple myeloma, aplastic anemia, others), application (peripheral blood stem cells transplant, bone marrow transplant, cord blood transplant), and end user (transplant centres, hospitals, specialty centres). Revenue coverage spans 2026 to 2036.

Hematopoietic Stem Cell Transplantation Market Exclusions

The scope does not include CAR-T cell therapy, gene therapy, or general oncology treatments not directly associated with the transplantation procedure.

Hematopoietic Stem Cell Transplantation Market Research Methodology

• Primary Research: FMI analysts conducted interviews with transplant physicians, transplant centre directors, and pharmaceutical procurement managers at hematopoietic stem cell transplant programmes.
• Desk Research: Combined data from transplant activity registries, pharmaceutical sales databases, and transplant centre utilization records.
• Market Sizing and Forecasting: Bottom-up sizing across transplant type, indication, and application segments with regional transplant activity curves.
• Data Validation: Cross-checked quarterly against CIBMTR, EBMT, and regional transplant registry data, pharmaceutical sales volumes, and transplant centre activity reports.

Why is the Hematopoietic Stem Cell Transplantation Market Growing?

• Expanding indication approvals and evolving conditioning regimens are increasing the number of patients eligible for hematopoietic stem cell transplantation across hematological malignancies and non-malignant conditions.
• Growth in international donor registries and alternative donor sources including haploidentical and cord blood transplants is increasing donor availability and transplant accessibility.
• Improving post-transplant supportive care including graft-versus-host disease prophylaxis is reducing transplant-related mortality and supporting broader clinical adoption.

Demand for hematopoietic stem cell transplantation reflects the expanding clinical indications, improving transplant outcomes, and growing accessibility of donor sources. HSCT remains the only curative treatment for many hematological malignancies and bone marrow failure syndromes, creating sustained demand proportional to disease incidence and transplant centre capacity.

Adoption of allogeneic transplantation leads at 57.3% of transplant type demand, reflecting the clinical preference for donor-sourced stem cells in indications where graft-versus-leukemia effect provides therapeutic benefit. Allogeneic transplants require donor matching and carry graft-versus-host disease risk, but offer superior relapse prevention in many hematological malignancies compared to autologous approaches.

Pricing reflects the comprehensive nature of HSCT, encompassing donor search and procurement, conditioning chemotherapy, the transplantation procedure itself, and extended post-transplant monitoring and supportive care. Total transplant episode costs vary significantly by transplant type, indication, and complication profile, with allogeneic transplants typically more expensive than autologous procedures.

Market Segmentation Analysis

• Allogeneic accounts for 57.3% of the transplant type segment.
• Acute Myeloid Leukemia represents 38.5% of the indication segment.
• Peripheral Blood Stem Cells Transplant leads the application segment with 47.6% share.

The hematopoietic stem cell transplantation market is segmented by transplant type, indication, application source, and end user. Demand is driven by disease incidence, transplant centre capacity, donor availability, and the evolving clinical evidence supporting transplant across expanding indications.

Insights into the Allogeneic Transplant Type Segment

Allogeneic transplantation leads at 57.3% due to the clinical preference for donor-sourced stem cells that provide graft-versus-disease benefit in hematological malignancies. Expanding donor registries, haploidentical transplant techniques, and cord blood banking are increasing allogeneic donor availability.

Insights into the Acute Myeloid Leukemia Indication Segment

Acute myeloid leukemia represents 38.5% of indication demand, reflecting its position as the most common indication for allogeneic HSCT. AML patients in first or second complete remission represent the largest single patient population referred for transplant evaluation.

Hematopoietic Stem Cell Transplantation Market Drivers, Restraints, and Opportunities

• Regulatory and structural demand drivers are creating sustained procurement patterns.
• Cost and access constraints create segmentation in adoption rates.
• Technology and product development are expanding the addressable market.

The hematopoietic stem cell transplantation market is shaped by regulatory, technology, and procurement dynamics.

Indication Expansion

Demand is shaped by expanding clinical indications for HSCT beyond traditional acute leukemia to include myelodysplastic syndromes, myeloproliferative neoplasms, and non-malignant conditions including hemoglobinopathies and primary immunodeficiencies.

Donor Source Diversification

Growth reflects the increasing availability of alternative donor sources including haploidentical family donors, unrelated donors through international registries, and cord blood units that reduce the donor availability barrier.

Post-Transplant Outcome Improvement

Adoption is supported by improving GVHD prophylaxis, infection management, and supportive care protocols that reduce transplant-related mortality and improve long-term survival, supporting broader clinical adoption.

Transplant Centre Capacity Constraints

Transplant centre capacity, including bed availability, transplant physician workforce, and support team resources, constrains transplant volumes in some regions despite growing clinical demand.

Analysis of Hematopoietic Stem Cell Transplantation Market By Key Countries

Country	CAGR
South Korea	8.0%
EU	7.9%
Japan	7.8%
UK	7.7%
USA	7.6%

• South Korea leads with 8.0% CAGR.
• EU at 7.9% reflects expanding capabilities.
• Japan (7.8%) and UK (7.7%) maintain steady growth.

The global hematopoietic stem cell transplantation market is expected to grow at 7.8% per year from 2026 to 2036.

Demand Outlook for Hematopoietic Stem Cell Transplantation Market in South Korea

South Korea is expected to grow at 8.0% through 2036, supported by expanding transplant centre capacity, growing donor registry participation, and advancing transplant technology adoption.

• Transplant centre expansion increases procedure capacity.
• Donor registry growth improves matching availability.
• Technology advancement supports transplant outcomes.

Future Outlook for Hematopoietic Stem Cell Transplantation Market in the European Union

The EU is expected to grow at 7.9% through 2036, driven by EBMT-coordinated transplant activity, cross-border donor sharing, and comprehensive transplant centre infrastructure.

• EBMT coordination supports cross-border collaboration.
• Donor sharing programs optimize matching opportunities.
• Transplant infrastructure provides comprehensive care.

In-depth Analysis of Hematopoietic Stem Cell Transplantation Market in Japan

Japan is expected to grow at 7.5% through 2036, supported by established transplant centres, cord blood banking infrastructure, and clinical research in transplant optimization.

• Established transplant centres provide clinical expertise.
• Cord blood banking supports alternative donor access.
• Clinical research advances transplant approaches.

Sales Analysis of Hematopoietic Stem Cell Transplantation Market in the United Kingdom

The UK is expected to grow at 7.3% through 2036, supported by NHS transplant commissioning, Anthony Nolan donor registry, and BSBMT clinical standards.

• NHS commissioning supports transplant programme funding.
• Anthony Nolan registry provides donor matching.
• Clinical standards guide transplant practice.

Opportunity Analysis of Hematopoietic Stem Cell Transplantation Market in the United States

The USA is expected to grow at 7.7% through 2036, driven by the highest transplant volume globally, NMDP/Be The Match donor registry, and advancing transplant research.

• Highest global transplant volume sustains market scale.
• NMDP donor registry provides extensive matching options.
• Transplant research advances clinical protocols.

Competitive Landscape and Strategic Positioning

• Pluristem Therapeutics Inc. leads with an estimated 20.1% market share.
• The competitive landscape includes global and specialized players.
• Entry barriers include regulatory, relationship, and scale factors.

Pluristem Therapeutics Inc. leads through its cell therapy and transplant support product portfolio addressing GVHD and engraftment complications.

CellGenix GmbH and Regen Biopharma Inc. maintain positions through transplant cell processing and supportive care products used in HSCT programmes.

Lonza Group and Sanofi compete on pharmaceutical manufacturing and supportive care product supply supporting conditioning regimens and post-transplant management.

Entry barriers include the specialized transplant medicine expertise, regulatory requirements for cell therapy products, and the established relationships between transplant centres and pharmaceutical suppliers.

Key Companies in the Hematopoietic Stem Cell Transplantation Market

Key global companies leading the hematopoietic stem cell transplantation market include:

• Pluristem Therapeutics Inc. (Israel), CellGenix GmbH (Germany), and Lonza Group (Switzerland) hold leading positions through cell therapy products and transplant support portfolios.
• Regen Biopharma Inc. (USA) and Sanofi (France) compete on transplant pharmaceuticals and supportive care products.
• Miltenyi Biotec (Germany), Takara Bio (Japan), and STEMCELL Technologies (Canada) represent cell processing and transplant technology positions.

Competitive Benchmarking: Hematopoietic Stem Cell Transplantation Market

Company	Cell Therapy Portfolio	Transplant Support Products	Manufacturing Scale	Geographic Reach
Pluristem Therapeutics Inc.	High	Medium	Medium	Global
CellGenix GmbH	Medium	High	Medium	Europe, Global
Regen Biopharma Inc.	Medium	Medium	Low	N. America
Lonza Group	Low	Medium	High	Global
Sanofi	Low	High	High	Global
Miltenyi Biotec	Medium	High	Medium	Europe, Global

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Hematopoietic Stem Cell Transplantation Market

• In 2025, Miltenyi Biotec continued to enhance its cell processing and separation technologies supporting hematopoietic stem cell transplantation workflows, contributing to improved efficiency and standardization in allogeneic HSCT preparation across transplant centers.
• In 2025, Pluristem Therapeutics Inc. continued clinical development of cell-based therapeutic approaches targeting complications associated with allogeneic hematopoietic stem cell transplantation, including graft-versus-host disease (GVHD), within broader regenerative medicine programs.

Key Players in the Hematopoietic Stem Cell Transplantation Market

Major Global Players

• Pluristem Therapeutics Inc.
• CellGenix GmbH
• Regen Biopharma Inc.
• Lonza Group
• Sanofi
• Taiga Biotechnologies, Inc.
• Takeda Pharmaceutical Company Limited

Emerging Players/Startups

• Miltenyi Biotec
• Takara Bio
• STEMCELL Technologies
• Medipost
• Mesoblast

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 8.78 billion to USD 18.61 billion, at a CAGR of 7.8%
Market Definition	The hematopoietic stem cell transplantation market covers clinical services, pharmaceutical products, and supportive care associated with bone marrow and stem cell transplantation procedures for hematological malignancies, bone marrow failure syndromes, and immune deficiency conditions. Services include donor matching, conditioning regimens, transplantation procedures, and post-transplant management.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries
Key Companies Profiled	Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Sanofi, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Talaris Therapeutics
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Hematopoietic Stem Cell Transplantation Market Market Segmented by Transplant Type:

• Allogeneic
• Autologous

Hematopoietic Stem Cell Transplantation Market Market Segmented by Indication:

• Acute Myeloid Leukemia
• Acute Lymphoblastic Leukemia
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• Multiple Myeloma
• Other Non-Malignant Disorders

Hematopoietic Stem Cell Transplantation Market Market Segmented by Application:

• Peripheral Blood Stem Cells Transplant
• Bone Marrow Transplant
• Cord Blood Transplant

Hematopoietic Stem Cell Transplantation Market Market Segmented by End User:

• Transplant Centers
  • Academic Hospitals
  • General Hospitals
  • Specialty Clinics

Hematopoietic Stem Cell Transplantation Market Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. Center for International Blood and Marrow Transplant Research. (2025). CIBMTR Annual Report: HSCT Activity and Outcomes. CIBMTR.
• 2. European Society for Blood and Marrow Transplantation. (2024). EBMT Activity Survey: European Transplant Statistics. EBMT.
• 3. National Marrow Donor Program. (2025). NMDP/Be The Match: Donor Registry and Transplant Activity Report. NMDP.
• 4. World Marrow Donor Association. (2024). WMDA Annual Report: International Donor Registry Statistics. WMDA.
• 5. World Health Organization. (2024). WHO Classification of Hematopoietic and Lymphoid Tumours. WHO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the market size and revenue from 2026 to 2036.
• Segmentation by transplant type, indication, application, and end user.
• Regional and country-level insights across more than 30 markets.
• Donor registry and stem cell source analysis.
• Competitive landscape assessment.
• Investment opportunity identification.
• Transplant outcome and clinical protocol analysis.
• Data delivery in PDF and Excel formats.